Navigation Links
ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
Date:8/28/2012

SAN DIEGO, Aug. 28, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 10, 2012 at 2:25 p.m. Eastern time, in the Starlight Center Salon at The Waldorf Astoria hotel in New York City.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.

About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function which is compromised in a wide range of serious and life-threatening diseases and conditions.  The Company initially is developing ANX-188 as a treatment for complications arising from sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.

(Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ADVENTRX Announces Appointment Of Chief Medical Officer
2. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
3. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
4. ADVENTRX Pharmaceuticals To Present At The OneMedForum New York 2012 Emerging Company Finance Conference On July 12
5. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
6. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
7. Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer
8. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
9. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
10. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
11. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... YORK , March 30, 2017  Purcell Julie & ... shareholders nationwide, is investigating a potential breach of fiduciary duty ... (NASDAQ: SGYP ). If you ... obtaining additional information regarding this investigation, free of charge, please ... ...
(Date:3/29/2017)... Wound care devices and products are used ... The industry mainly consists of establishments engaged in manufacturing ... wounds caused by mechanical, chemical, thermal, and radiogenic trauma; ... diabetes, skin related diseases, immunological diseases, and other chronic ... the largest region in the wound care devices market ...
(Date:3/29/2017)... 2017 Global intravenous (IV) iron and oral iron ... growing at a CAGR of 5%. Iron ... to treat anemia or other iron deficiencies. Oral iron supplements ... However, in some cases, oral administrations are not capable of ... iron therapy comes into the picture. Global Intravenous ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... March 30, 2017 , ... ... educational offerings of corporate finance programs to address the increasingly complex educational needs ... executives increase their knowledge of sophisticated corporate finance and will increase their ability ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... of Nutrition and Dietetics (AND), will join nonprofit Seafood Nutrition Partnership (SNP) in ... live webinar designed to help nutrition educators and students inform consumers about the ...
(Date:3/29/2017)... ... 2017 , ... During the last week of March, Chad Kawa, MD of ... in the local community. , Colon cancer is the second leading cause of ... while it is small, confined and easier to treat. If you are 50 or ...
(Date:3/29/2017)... City, NY (PRWEB) , ... March 29, 2017 ... ... for men’s and women’s professional squash, announced it has enlisted New York City-based ... The agency will develop and procure sponsorship opportunities for the Professional Squash ...
(Date:3/29/2017)... MD (PRWEB) , ... March 30, 2017 , ... CHARM ... Charm City Run has announced that Mercy Medical Center will serve as the official ... the Mid-Atlantic region. On Sunday, June 25, 2017, thousands of women will walk or ...
Breaking Medicine News(10 mins):